Henry Schein raises 2026 non-GAAP EPS view to $5.50–$5.56
The revised 2026 outlook raises the non-GAAP EPS range and Adjusted EBITDA growth view while leaving the sales-growth range unchanged.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Henry Schein (HSIC) reported third-quarter 2026 sales of $3.471 billion, up 4.0% year over year, and raised full-year non-GAAP diluted EPS guidance to $5.50 to $5.56 from $5.29 to $5.39. U.S. dental merchandise sales grew 8.6%, driven primarily by volume from market-share gains. GAAP diluted EPS was $1.06, up 26.2%; non-GAAP diluted EPS was $1.56, up 13.0%.
Non-GAAP diluted EPS excluding the $0.19-per-share Q3 tariff-refund benefit and the prior-year $0.23-per-share remeasurement gain was $1.37 versus $1.15, up 19.1%. Adjusted EBITDA was $321 million versus $295 million, with a 9.24% margin, up 40 basis points. Nine-month operating cash flow was $306 million versus $331 million. The 2026 sales-growth outlook remains 4.5% to 5.5%; Adjusted EBITDA growth guidance shifted to high-single-digits from mid-to-high-single-digits. Guidance covers current continuing operations and assumes no significant tariff refunds or remeasurement gains for the rest of 2026, while including targeted, limited fourth-quarter growth investments.
1 point · 0 major0 major · 1 point
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointQ3 GAAP diluted EPS rose 26.2% to $1.06.
Negative
- Moderate pointNine-month operating cash flow fell to $306 million from $331 million.
Filing Explained
Henry Schein repurchased and retired about 1.4 million common shares for $125 million in Q3, reducing shares outstanding; separately, $330 million remained authorized and available at quarter-end for future repurchases, not purchases disclosed here.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Q3 net sales: $3.471 billion
GAAP diluted EPS: $1.06 per diluted share
Non-GAAP diluted EPS: $1.56 per diluted share
+5 more
8 metrics
Q3 net sales
$3.471 billion
Third quarter 2026; total sales growth was 4.0% versus the prior-year quarter.
GAAP diluted EPS
$1.06 per diluted share
Third quarter 2026; up 26.2% versus the prior-year quarter.
Non-GAAP diluted EPS
$1.56 per diluted share
Third quarter 2026; up 13.0% versus the prior-year quarter.
Adjusted EBITDA
$321 million
Third quarter 2026, compared with $295 million in the prior-year quarter; margin was 9.24%, up 40 basis points.
Operating cash flow
$306 million
First nine months of 2026, compared with $331 million in the prior-year period.
FY2026 non-GAAP diluted EPS guidance
$5.50 to $5.56 per diluted share
Raised from prior guidance of $5.29 to $5.39.
U.S. dental merchandise sales growth
8.6%
Third quarter 2026; growth was driven primarily by volume from market-share gains.
Q3 shares repurchased
Approximately 1.4 million shares
Average price of $86.67 per share; total of $125 million.
Key Terms
internal sales growth, Adjusted EBITDA, non-GAAP diluted EPS, remeasurement gains, +1 more
5 terms
internal sales growth financial
"calculated from total net sales using constant foreign currency exchange rates"
Adjusted EBITDA financial
"Adjusted EBITDA margin growing 40 basis points to 9.24%"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
non-GAAP diluted EPS financial
"Non-GAAP diluted EPS attributable to Henry Schein, Inc."
Non-GAAP diluted EPS (Earnings Per Share) is a measure of a company's profit allocated to each share of stock, calculated using adjusted earnings that exclude certain items like one-time expenses or gains. It provides a view of ongoing performance by removing irregular or non-recurring factors. Investors use it to better understand the company's core profitability and compare performance across different periods or companies.
remeasurement gains financial
"Remeasurement gains, net of tax"
contingent consideration financial
"Change in contingent consideration"
Contingent consideration is an additional payment agreed when one company buys another that will be paid later only if specific future targets are met, such as revenue, profit, or regulatory milestones. It matters to investors because it shifts risk between buyer and seller and affects the acquiring company's future cash flow and reported value — like promising a bonus after results are proven.
Earnings Snapshot
Net sales: $3.471 billion · Guidance included
Third quarter ended September 26, 2026
Net sales
$3.471 billion
Up 4.0% year over year.
GAAP diluted EPS
$1.06 per diluted share
Up 26.2% year over year.
Non-GAAP diluted EPS
$1.56 per diluted share
Up 13.0% year over year.
Adjusted EBITDA
$321 million
Compared with $295 million in the prior-year quarter; margin grew 40 basis points to 9.24%.
Operating cash flow, first nine months
$306 million
Compared with $331 million in the prior-year period.
Guidance
FY2026 non-GAAP diluted EPS of $5.50 to $5.56; sales growth of 4.5% to 5.5%; Adjusted EBITDA growth at high-single-digits. Guidance covers current continuing operations, includes targeted, limited fourth-quarter growth investments, and assumes no significant tariff refunds or remeasurement gains for the remainder of 2026.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were HSIC's third-quarter 2026 sales and EPS?
Henry Schein reported sales of $3.471 billion, up 4.0% year over year. GAAP diluted EPS was $1.06, up 26.2%, while non-GAAP diluted EPS was $1.56, up 13.0%. U.S. dental merchandise sales grew 8.6%, driven primarily by volume from market-share gains.
What is HSIC's updated 2026 earnings guidance?
Henry Schein raised its 2026 non-GAAP diluted EPS guidance to $5.50 to $5.56 from $5.29 to $5.39. Adjusted EBITDA growth guidance changed from mid-to-high-single-digits to high-single-digits, while the sales-growth range remained 4.5% to 5.5%. The guidance covers current continuing operations and assumes no significant tariff refunds or remeasurement gains for the remainder of 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
,
,
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (
)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
The
Nasdaq
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 2.02. Results of Operations and Financial Condition.
On November 3, 2026, Henry Schein, Inc. issued a press release reporting the financial results for the three and
nine months ended September 26, 2026. The full text of the press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
The information in this Item 2.02 and the press release attached as Exhibit 99.1 are considered furnished to the
Securities and Exchange Commission and are not deemed filed for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended.
Item 9.01. Financial Statements and Exhibits
(a) Not applicable.
(b) Not applicable.
(c) Not applicable.
(d) Exhibit 99.1 – Press Release dated November 3, 2026.
Exhibit 104 - Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
HENRY SCHEIN, INC.
By:
/s/ Ronald N. South
Ronald N. South
Senior Vice President and
Chief Financial Officer
(Authorized Signatory and Principal
Financial and Accounting Officer)
November 3, 2026
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press Release dated November 3, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
-1-
more
FOR IMMEDIATE RELEASE
HENRY SCHEIN REPORTS STRONG 2026 THIRD QUARTER AND RAISES FY2026 GUIDANCE
●
Q3 2026 GAAP diluted EPS of $1.06, up 26.2% versus prior year; Q3 2026 non-GAAP diluted EPS of $1.56,
up 13.0% versus prior year
●
4.0% total sales growth, driven by 8.6% U.S. dental merchandise sales growth due primarily to volume from
market share gains
●
Raises FY2026 guidance for non-GAAP diluted EPS
(A)
high-single-digits reflecting strong operating performance, net tariff refund benefits, and targeted, limited
growth-investments
MELVILLE, N.Y., November 3, 2026 –
Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of healthcare
solutions to office-based dental and medical practitioners, today reported financial results for the third quarter ended
September 26, 2026. The Company reported $3.5 billion in sales with total growth of 4.0%, and 3.1% internally in local
currencies. GAAP earnings per share grew 26.2% versus the prior year. Non-GAAP earnings per share grew 13.0%, or
19.1% when excluding current-quarter net tariff refunds and the prior-year remeasurement gains (refer to Exhibit D).
“We delivered another strong quarter that increases our confidence in the momentum we are building at Henry
Schein. I am very pleased with the U.S. dental merchandise sales growth of 8.6% driven primarily by volume in a stable
market and our 19%
adjusted earnings per share growth
4
,” said Fred Lowery, Chief Executive Officer of Henry Schein.
“Our strategy is translating into stronger financial results. We are gaining share in key businesses, improving our portfolio
mix, maintaining a disciplined approach to capital allocation, and realizing the benefits of our value creation initiatives,”
Mr. Lowery added.
Third Quarter 2026 Financial Results
●
Total net sales
2025, reflecting 3.1% internal sales growth, 0.7% sales growth from acquisitions, and a 0.2% increase resulting
from foreign currency exchange. Third quarter sales growth is detailed in Exhibit A
1
.
●
Global Distribution and Value-Added Services sales
internal sales growth, 0.5% sales growth from acquisitions, and a 0.3% increase from foreign currency exchange
compared with the third quarter of 2025. The main components compared with the third quarter of 2025 are:
●
Global Dental Distribution merchandise sales
internal sales growth, compared with the third quarter of 2025.
-2-
more
●
Global Dental Distribution equipment sales
internal sales growth, compared with the third quarter of 2025.
●
Global Medical Distribution sales
growth, compared with the third quarter of 2025.
●
Global Value-Added Services sales
for the
quarter decreased 4.8%, on both a reported and internal
sales growth basis, compared with the third quarter of 2025.
●
Global Specialty Products sales
2.6% sales growth from acquisitions, and a 0.1% increase resulting from foreign currency exchange, compared
with the third quarter of 2025.
●
Global Technology sales
decrease due to a business disposal, and no impact from foreign currency exchange, compared with the third quarter
of 2025.
●
GAAP net income
2
share
3
, up 26.2% compared with the third quarter of 2025.
●
Non-GAAP net income
2
for the quarter was $175 million. Non-GAAP diluted earnings per share were $1.56 per
diluted share, up 13.0% compared with the third quarter of 2025.
●
The Company recognized a $0.19
per diluted share
3,4
in the third quarter of 2026,
and a $0.23 per diluted share
3,4
in the third quarter of 2025, included in our GAAP and non-
GAAP results.
●
Excluding these items, non-GAAP diluted EPS was $1.37
4
4
increase of 19.1%.
●
Adjusted EBITDA
5
of $295 million, with Adjusted EBITDA margin growing 40 basis points to 9.24%.
Year -to-Date Financial Results
●
Total net sales
first nine months of 2025, reflecting 3.4% internal sales growth, 0.7% sales growth from acquisitions, and a 1.5%
increase resulting from foreign currency exchange. Year-to-date sales growth is detailed in Exhibit A
1
.
●
GAAP net income
2
$2.80 per diluted share
3
, up 15.7% compared with the first nine months of 2025.
●
Non-GAAP net income
2
for the first nine months of 2026 was $473 million. Non-GAAP diluted earnings per
share were $4.14
per diluted share
3
, up 14.0% compared with the first nine months of 2025.
●
Adjusted EBITDA
5
the first nine months of 2025 of $810 million, with Adjusted EBITDA margin growing 41 basis points to 8.72%.
-3-
more
Share Repurchases
During the third quarter of 2026, the Company repurchased approximately 1.4 million shares of common stock at an
average price of $86.67 per share for a total of $125 million.
For the year-to-date, the Company repurchased approximately 5.7 million shares of common stock at an average
price of $79.50 per share for a total of $450 million.
At the end of the quarter, Henry Schein had approximately $330 million authorized and available for future stock
repurchases.
2026 Financial Guidance
Henry Schein today raised its financial guidance for 2026. Guidance is for current continuing operations and does not
include the impact of restructuring expenses and related costs, amortization expense of acquired intangible assets, the
impairment of intangible assets, changes in contingent consideration, select implementation-related costs supporting value
creation initiatives, and litigation settlements. This guidance also assumes that foreign currency exchange rates remain
generally consistent with current levels.
The Company’s FY2026 non-GAAP diluted EPS guidance includes the net benefit from tariff refunds recognized in
the third quarter, targeted and limited growth-investments in the fourth quarter which will contribute to growth in 2027, and
improved underlying business performance. The updated guidance assumes no significant tariff refunds or remeasurement
gains for the remainder of 2026. The changes to the Company’s financial guidance are summarized below:
2026 non-GAAP diluted EPS
3
$5.50 to $5.56 $5.29 to $5.39
2026 total sales growth 4.5% to 5.5% 4.5% to 5.5%
2026 Adjusted EBITDA growth High-single- Mid to high-
(A) Adjustments to 2026 GAAP Net Income and Diluted EPS
The Company is providing guidance for 2026 diluted EPS and for 2026 Adjusted EBITDA on a non-GAAP basis, as
noted above. The Company is not providing a reconciliation of its 2026 non-GAAP diluted EPS guidance to its projected
2026 diluted EPS prepared on a GAAP basis, or its 2026 Adjusted EBITDA guidance to net income prepared on a GAAP
basis. This is because the Company is unable to provide without unreasonable effort an estimate of restructuring expenses
and related or similar costs, including its ongoing value creation initiatives, and the corresponding tax effect, which will be
included in the Company’s 2026 diluted EPS and net income, prepared on a GAAP basis. The inability to provide this
reconciliation is due to the uncertainty and inherent difficulty of predicting the occurrence, magnitude, financial impact and
timing of related costs.
-4-
more
Management does not believe these items are representative of the Company’s underlying business performance. For
the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be
material to future results.
Third-Quarter 2026 Conference Call Webcast
The Company will hold a conference call to discuss third-quarter 2026 financial results today, beginning at 8:00 a.m.
Eastern time. Individual investors are invited to listen to the conference call through Henry Schein’s website by visiting
https://investor.henryschein.com/webcasts. In addition, a replay will be available beginning shortly after the call has ended
for a period of one week.
The Company will be posting slides that provide a summary of its third-quarter 2026 financial results on its website
at https://investor.henryschein.com/financials/quarterly-results/
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is a products, services, and technology platforms company for healthcare
customers. With approximately 25,000 Team Schein Members worldwide, the Company's network of trusted advisors
provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success
and clinical outcomes. Our Business, Clinical, Technology and Supply Chain solutions help office-based dental and medical
practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental
laboratories, government and institutional health care clinics, as well as other alternate care sites.
Henry Schein operates through a centralized and automated distribution network, with a selection of more than
300,000 branded products and Henry Schein corporate brand products in our main distribution centers.
A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville,
N.Y., and has operations or affiliates in 34 countries and territories. The Company's sales reached $13.2 billion in 2025, and
have grown at a compound annual rate of approximately 11.0 percent since Henry Schein became a public company in 1995.
For more information, visit Henry Schein at www.henryschein.com.
Cautionary Note Regarding Forward-Looking Statements and Use of Non-GAAP Financial Information
In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we provide the
following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the
forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are
subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be
materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
expectations, and are generally identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,”
“forecast,” “project,” “anticipate,” “to be,” “to make”, or other comparable terms. A fuller discussion of our operations, financial
condition and status of litigation matters, including factors that may affect our business and future prospects, is contained in documents
we file with the United States Securities and Exchange Commission, or SEC, including our Annual Report on Form 10-K, and will be
contained in subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause
our actual performance to differ materially from current expectations.
-5-
more
Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but
are not limited to: our dependence on third parties for the manufacture and supply of our products and where we manufacture products,
our dependence on third parties for raw materials or purchased components; risks relating to the achievement of our strategic growth
objectives, including anticipated results of restructuring and value creation initiatives; risks related to the Strategic Partnership Agreement
with KKR Hawaii Aggregator L.P. entered into in January 2025; transitions in senior company leadership (including, without limitation,
our Chief Executive Officer, Chief Financial Officer, and other executive officers); our ability to develop or acquire and maintain and
protect new products (particularly technology and specialty products) and services and utilize new technologies that achieve market
acceptance with acceptable margins; transitional challenges associated with acquisitions and joint ventures, including the failure to
achieve anticipated synergies/benefits, as well as significant demands on our operations, information systems, legal, regulatory,
compliance, financial and human resources functions in connection with acquisitions, dispositions and joint ventures; certain provisions in
our governing documents that may discourage third-party acquisitions of us; adverse changes in supplier rebates or other purchasing
incentives; risks related to the sale of corporate brand products; risks related to activist investors; security risks associated with our
information systems and technology products and services, such as cyberattacks or other privacy or data security breaches (including the
October 2023 incident); effects of a highly competitive (including, without limitation, competition from third-party online commerce
sites) and consolidating market; political, economic, and regulatory influences on the health care industry; risks from expansion of
customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with
our third-party shippers, and increases in fuel and energy costs; changes in laws and policies governing manufacturing, development and
investment in territories and countries where we do business; general global and domestic macro-economic and political conditions,
including inflation, deflation, recession, unemployment (and corresponding increase in under-insured populations), consumer confidence,
sovereign debt levels, fluctuations in energy pricing and the value of the U.S. dollar as compared to foreign currencies and changes to
other economic indicators; failure to comply with existing and future regulatory requirements, including relating to health care; risks
associated with the EU Medical Device Regulation; failure to comply with laws and regulations relating to health care fraud or other laws
and regulations; failure to comply with laws and regulations relating to the collection, storage and processing of sensitive personal
information or standards in electronic health records or transmissions; changes in tax legislation, changes in tax rates and availability of
certain tax deductions; risks related to product liability, intellectual property and other claims; risks associated with customs policies or
legislative import restrictions; risks associated with disease outbreaks, epidemics, pandemics (such as the COVID-19 pandemic), or
similar wide-spread public health concerns and other natural or man-made disasters; risks associated with our global operations; the threat
or outbreak of war (including, without limitation, geopolitical wars), terrorism or public unrest (including, without limitation, the wars in
Ukraine and Iran, the Israel-Gaza conflict and other unrest and threats in the Middle East and the possibility of a wider European or global
conflict); changes to laws and policies governing foreign trade, tariffs and sanctions or greater restrictions on imports and exports,
including changes to international trade agreements and the current imposition of (and the potential for additional) tariffs by the U.S. on
numerous countries and retaliatory tariffs; supply chain disruption; litigation risks; new or unanticipated litigation developments and the
status of litigation matters; our dependence on our senior management, employee hiring and retention, increases in labor costs or health
care costs, and our relationships with customers, suppliers and manufacturers; and disruptions in financial markets. The order in which
these factors appear should not be construed to indicate their relative importance or priority.
We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict.
Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake
no duty and have no obligation to update forward-looking statements except as required by law.
Income prepared under generally accepted accounting principles (GAAP). These non-GAAP financial measures adjust the Company’s
actual results prepared under GAAP to exclude certain items. In the schedule attached to the press release, the non-GAAP measures have
been reconciled to and should be considered together with the Consolidated Statements of Income. Management believes that non-GAAP
financial measures provide investors with useful supplemental information about the financial performance of our business, enable
comparison of financial results between periods where certain items may vary independent of business performance and allow for greater
transparency with respect to key metrics used by management in operating our business. The impact of certain items that are excluded
include integration and restructuring costs, amortization of acquisition-related assets, the insurance claim recovery associated with the
cybersecurity incident, changes in contingent consideration, costs associated with shareholder advisory matters and select value creation
consulting costs, and litigation settlements because the amount and timing of such charges are significantly impacted by the timing, size,
number and nature of the acquisitions we consummate and occur on an unpredictable basis. These non-GAAP financial measures are
presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding, similarly
captioned, GAAP measures.
1
See Exhibit A for details of sales growth. Internal sales growth is calculated from total net sales using constant foreign
currency exchange rates and excludes sales from acquisitions.
2
3
References to diluted EPS refer to diluted EPS attributable to Henry Schein, Inc.
4
5
-6-
more
CONTACTS: Investors
Ronald N. South
Senior Vice President and Chief Financial Officer
ronald.south@henryschein.com
(631) 843-5500
Graham Stanley
Vice President, Investor Relations and Strategic Financial Project Officer
graham.stanley@henryschein.com
(631) 843-5500
Media
Tim Vassilakos
Vice President, Global Corporate Communications
timothy.vassilakos@henryschein.com
(516) 510-0926
(TABLES TO FOLLOW)
-7-
more
HENRY SCHEIN, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(in millions, except share and per share data)
(unaudited)
Three Months Ended
Nine Months Ended
September 26,
September 27,
September 26,
September 27,
2026
2025
2026
2025
Net sales
$
3,471
$
3,339
$
10,297
$
9,747
Cost of sales
2,366
2,313
7,021
6,705
Gross profit
1,105
1,026
3,276
3,042
Operating expenses:
Selling, general and administrative
819
760
2,459
2,276
Depreciation and amortization
71
68
208
194
Restructuring and related costs
22
34
63
82
Operating income
193
164
546
490
Other income (expense):
Interest income
9
9
24
24
Interest expense
(42)
(38)
(124)
(111)
Other, net
-
(1)
1
(3)
Income before taxes, equity in earnings of affiliates and
noncontrolling interests
160
134
447
400
Income taxes
(37)
(28)
(109)
(94)
Equity in earnings of affiliates, net of tax
3
3
2
10
Net income
126
109
340
316
Less: Net income attributable to noncontrolling interests
(7)
(8)
(20)
(19)
Net income attributable to Henry Schein, Inc.
$
119
$
101
$
320
$
297
Earnings per share attributable to Henry Schein, Inc.:
Basic
$
1.07
$
0.84
$
2.83
$
2.44
Diluted
$
1.06
$
0.84
$
2.80
$
2.42
Weighted-average common shares outstanding:
Basic
111,272,868
120,199,552
113,220,442
121,965,991
Diluted
112,538,936
121,036,247
114,338,114
122,840,062
-8-
more
HENRY SCHEIN, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions, except share data)
September 26,
December 27,
2026
2025
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents
$
184
$
156
Accounts receivable, net of allowance for credit losses of $103 and $90
1,875
1,651
Inventories, net
2,050
2,002
Prepaid expenses and other
667
655
Total current assets
4,776
4,464
Property and equipment, net
619
621
Operating lease right-of-use assets
336
301
Goodwill
4,270
4,213
Other intangibles, net
921
1,018
Investments and other
588
598
Total assets
$
11,510
$
11,215
LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND
STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
$
1,203
$
1,154
Bank credit lines
1,000
764
Current maturities of long-term debt
142
33
Operating lease liabilities
79
78
Accrued expenses:
Payroll and related
325
340
Taxes
191
179
Other
658
680
Total current liabilities
3,598
3,228
Long-term debt
2,382
2,310
Deferred income taxes
152
146
Operating lease liabilities
288
251
Other liabilities
359
486
Total liabilities
6,779
6,421
Redeemable noncontrolling interests
914
895
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.01 par value, 1,000,000 shares authorized,
none outstanding
-
-
Common stock, $0.01 par value, 480,000,000 shares authorized,
110,538,632 issued and outstanding on September 26, 2026 and
115,771,149 issued and outstanding on December 27, 2025
1
1
Additional paid-in capital
140
177
Retained earnings
3,205
3,293
Accumulated other comprehensive loss
(187)
(226)
Total Henry Schein, Inc. stockholders' equity
3,159
3,245
Noncontrolling interests
658
654
Total stockholders' equity
3,817
3,899
Total liabilities, redeemable noncontrolling interests and stockholders' equity
$
11,510
$
11,215
-9-
more
HENRY SCHEIN, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions)/(unaudited)
Three Months Ended
Nine Months Ended
September 26,
September 27,
September 26,
September 27,
2026
2025
2026
2025
Cash flows from operating activities:
Net income
$
126
$
109
$
340
$
316
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation and amortization
86
80
251
229
Impairment charge on intangible assets
-
-
-
1
Non-cash restructuring charges
-
4
4
7
Stock-based compensation expense
10
13
26
29
Provision for losses on trade and other accounts receivable
8
4
16
9
Provision for (benefit from) deferred income taxes
6
7
(2)
-
Equity in earnings of affiliates
(3)
(3)
(2)
(10)
Distributions from equity affiliates
2
1
6
9
Changes in unrecognized tax benefits
(13)
7
(17)
6
Other
(5)
(13)
(26)
(44)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable
(122)
(98)
(238)
(198)
Inventories
8
4
(41)
(25)
Other current assets
(31)
(40)
(21)
(3)
Accounts payable and accrued expenses
89
99
10
5
Net cash provided by operating activities
161
174
306
331
Cash flows from investing activities:
Purchases of property and equipment
(30)
(33)
(85)
(96)
Payments related to equity investments and business acquisitions,
net of cash acquired
-
(11)
(30)
(112)
Proceeds from loan to affiliate
1
-
3
2
Capitalized software costs
(15)
(12)
(45)
(38)
Other
(1)
-
(16)
(9)
Net cash used in investing activities
(45)
(56)
(173)
(253)
Cash flows from financing activities:
Net change in bank credit lines
(24)
9
237
257
Proceeds from issuance of long-term debt
95
70
239
314
Principal payments for long-term debt
(10)
(7)
(60)
(28)
Debt issuance costs
(3)
-
(3)
(2)
Proceeds from issuance of stock upon exercise of stock options
2
-
4
1
Payments for repurchases and retirement of common stock
(125)
(203)
(450)
(650)
Issuance of common stock
-
-
-
250
Payments for taxes related to shares withheld for employee taxes
(3)
-
(15)
(14)
Proceeds from (distributions to) noncontrolling shareholders
(22)
6
(44)
(12)
Payments for contingent consideration
-
-
(4)
(19)
Acquisitions of noncontrolling interests in subsidiaries
-
(2)
(42)
(79)
Net cash provided by (used in) financing activities
(90)
(127)
(138)
18
Effect of exchange rate changes on cash and cash equivalents
1
-
33
(82)
Net change in cash and cash equivalents
27
(9)
28
14
Cash and cash equivalents, beginning of period
157
145
156
122
Cash and cash equivalents, end of period
$
184
$
136
$
184
$
136
-10-
more
Exhibit A - Third Quarter Sales
Henry Schein, Inc.
2026 Third Quarter
Sales Summary
(in millions)
(unaudited)
Q3 2026 over Q3 2025
Constant Currency
Growth
Q3 2026
Q3 2025
Local
Internal
Growth
Acquisition
/(Disposition)
Growth
Total
Constant
Currency
Growth
Foreign
Exchange
Impact
Total Sales
Growth
U.S. Distribution and Value-Added
Services
Merchandise
$
660
$
607
7.0%
1.6%
8.6%
0.0%
8.6%
Equipment
220
217
1.6%
0.0%
1.6%
0.0%
1.6%
Value-Added Services
53
57
-7.6%
0.0%
-7.6%
0.0%
-7.6%
Total Dental
933
881
4.7%
1.2%
5.9%
0.0%
5.9%
Medical
1,110
1,099
1.0%
0.0%
1.0%
0.0%
1.0%
Total U.S. Distribution and Value-Added
Services
2,043
1,980
2.6%
0.6%
3.2%
0.0%
3.2%
International Distribution and Value-
Added Services
Merchandise
635
603
3.3%
0.9%
4.2%
1.2%
5.4%
Equipment
229
223
3.2%
0.0%
3.2%
-0.3%
2.9%
Value-Added Services
9
7
15.7%
0.0%
15.7%
0.7%
16.4%
Total Dental
873
833
3.4%
0.7%
4.1%
0.8%
4.9%
Medical
28
27
2.0%
0.0%
2.0%
2.2%
4.2%
Total International Distribution and
Value-Added Services
901
860
3.3%
0.7%
4.0%
0.8%
4.8%
Global Distribution and Value-Added
Services
Global Merchandise
1,295
1,210
5.1%
1.3%
6.4%
0.6%
7.0%
Global Equipment
449
440
2.4%
0.0%
2.4%
-0.1%
2.3%
Global Value-Added Services
62
64
-4.8%
0.0%
-4.8%
0.0%
-4.8%
Global Dental
1,806
1,714
4.1%
0.9%
5.0%
0.4%
5.4%
Global Medical
1,138
1,126
1.0%
0.0%
1.0%
0.1%
1.1%
Total Global Distribution and Value-
Added Services
2,944
2,840
2.9%
0.5%
3.4%
0.3%
3.7%
Global Specialty Products
391
369
3.4%
2.6%
6.0%
0.1%
6.1%
Global Technology
181
173
6.5%
-1.3%
5.2%
0.0%
5.2%
Eliminations
(45)
(43)
n/a
n/a
n/a
n/a
n/a
Total Global
$
3,471
$
3,339
3.1%
0.7%
3.8%
0.2%
4.0%
-11-
more
Exhibit A - Year-to-Date Sales
Henry Schein, Inc.
2026 Third Quarter Year-to-Date
Sales Summary
(in millions)
(unaudited)
Q3 2026 Year-to-Date over Q3 2025 Year-to-Date
Constant Currency
Growth
Q3 2026
Q3 2025
Local
Internal
Growth
Acquisition
/(Disposition)
Growth
Total
Constant
Currency
Growth
Foreign
Exchange
Impact
Total Sales
Growth
U.S. Distribution and Value-Added
Services
Merchandise
$
1,936
$
1,800
5.9%
1.6%
7.5%
0.0%
7.5%
Equipment
630
623
1.2%
0.0%
1.2%
0.0%
1.2%
Value-Added Services
152
153
-0.6%
0.0%
-0.6%
0.0%
-0.6%
Total Dental
2,718
2,576
4.4%
1.1%
5.5%
0.0%
5.5%
Medical
3,180
3,117
2.0%
0.0%
2.0%
0.0%
2.0%
Total U.S. Distribution and Value-Added
Services
5,898
5,693
3.1%
0.5%
3.6%
0.0%
3.6%
International Distribution and Value-
Added Services
Merchandise
1,988
1,813
3.5%
1.0%
4.5%
5.2%
9.7%
Equipment
692
640
4.1%
0.0%
4.1%
4.0%
8.1%
Value-Added Services
28
21
18.1%
4.9%
23.0%
5.9%
28.9%
Total Dental
2,708
2,474
3.8%
0.7%
4.5%
4.9%
9.4%
Medical
88
80
4.1%
0.0%
4.1%
6.4%
10.5%
Total International Distribution and
Value-Added Services
2,796
2,554
3.8%
0.7%
4.5%
5.0%
9.5%
Global Distribution and Value-Added
Services
Global Merchandise
3,924
3,613
4.7%
1.3%
6.0%
2.6%
8.6%
Global Equipment
1,322
1,263
2.7%
0.0%
2.7%
2.0%
4.7%
Global Value-Added Services
180
174
1.8%
0.6%
2.4%
0.7%
3.1%
Global Dental
5,426
5,050
4.1%
0.9%
5.0%
2.4%
7.4%
Global Medical
3,268
3,197
2.0%
0.1%
2.1%
0.1%
2.2%
Total Global Distribution and Value-
Added Services
8,694
8,247
3.3%
0.6%
3.9%
1.5%
5.4%
Global Specialty Products
1,207
1,122
2.6%
2.7%
5.3%
2.3%
7.6%
Global Technology
535
502
7.5%
-1.3%
6.2%
0.6%
6.8%
Eliminations
(139)
(124)
n/a
n/a
n/a
n/a
n/a
Total Global
$
10,297
$
9,747
3.4%
0.7%
4.1%
1.5%
5.6%
-12-
more
Exhibit B
Henry Schein, Inc.
2026 Third Quarter and Year -to-Date
Reconciliation of reported GAAP net income and diluted EPS attributable to Henry Schein, Inc.
to non-GAAP net income and diluted EPS attributable to Henry Schein, Inc.
(in millions, except per share data)
(unaudited)
Third Quarter
Year-to-Date
%
%
2026
2025
Growth
2026
2025
Growth
Net income attributable to Henry Schein, Inc.
$
119
$
101
17.1
%
$
320
$
297
7.6
%
Diluted EPS attributable to Henry Schein, Inc.
$
1.06
$
0.84
26.2
%
$
2.80
$
2.42
15.7
%
Non-GAAP Adjustments, net of tax and attribution to
noncontrolling interests
Restructuring and related costs (1)
$
16
$
25
$
44
$
58
Acquisition intangible amortization (2)
26
27
81
81
Cyber incident-insurance proceeds, net of third-party advisory
expenses (3)
-
-
-
(15)
Change in contingent consideration (4)
-
5
-
3
Costs associated with shareholder advisory matters and select
implementation related value creation consulting costs (5)
14
7
28
18
Litigation settlements (6)
-
1
-
2
Impairment of intangible assets (7)
-
-
-
1
Non-GAAP adjustments to net income
$
56
$
65
$
153
$
148
Non-GAAP net income attributable to Henry Schein, Inc.
$
175
$
167
4.7
%
$
473
$
445
6.2
%
Non-GAAP diluted EPS attributable to Henry Schein, Inc.
$
1.56
$
1.38
13.0
%
$
4.14
$
3.63
14.0
%
Management believes that non-GAAP financial measures provide investors with useful supplemental information about the financial
performance of our business, enable comparison of financial results between periods where certain items may vary independent of
business performance and allow for greater transparency with respect to key metrics used by management in operating our business.
These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a
replacement for corresponding, similarly captioned, GAAP measures. Net income growth rates are based on actual values and may not
recalculate due to rounding. Amounts may not sum due to rounding.
(1)
Restructuring and Related Costs
The following table presents details of our restructuring and related costs:
Third Quarter
Year -to-Date
2026
2025
2026
2025
Restructuring and related costs - pre-tax, as reported
$
22
$
34
$
63
$
82
Income tax benefit
(5)
(9)
(15)
(21)
Amount attributable to noncontrolling interests
(1)
-
(4)
(3)
Restructuring and related costs, net
$
16
$
25
$
44
$
58
-13-
more
(2)
Acquisition Intangible Amortization
The following table presents details of amortization of acquired intangible assets:
Third Quarter
Year -to-Date
2026
2025
2026
2025
Acquisition intangible amortization - pre-tax, as reported
$
44
$
46
$
135
$
133
Income tax benefit
(11)
(12)
(34)
(33)
Amount attributable to noncontrolling interests
(7)
(7)
(20)
(19)
Acquisition intangible amortization, net
$
26
$
27
$
81
$
81
(3)
Represents cyber insurance proceeds, net of one time professional and other fees related to remediation of our Q4 2023
cyber incident. During Q1 2025, we received insurance proceeds of $20 million ($15 million, net of taxes) under this
policy representing the remaining insurance recovery of losses related to the cyber incident.
(4)
Represents a change in the fair value of contingent consideration of $1 million ($0 million, net of taxes) and $0 million
($0 million, net of taxes) recorded during Q3 2026 and YTD 2026, respectively, and $7 million ($5 million, net of
taxes) and $5 million ($3 million, net of taxes) recorded during Q3 2025 and YTD 2025, respectively, related to certain
2023, 2024 and 2025 acquisitions.
(5)
Represents costs associated with shareholder advisory matters and select value creation consulting costs of $18 million
($14 million, net of taxes) and $37 million ($28 million, net of taxes) recorded during Q3 2026 and YTD 2026,
respectively, and $10 million ($7 million, net of taxes) and $24 million ($18 million, net of taxes) recorded during Q3
2025 and YTD 2025, respectively.
(6)
Represents settlement amounts for litigation related to certain opioid related lawsuits during Q3 2025 and YTD 2025
and a settlement at one of our businesses.
(7)
Represents impairment charges recorded in Q1 2025 on certain intangible assets.
-14-
more
Exhibit C
Henry Schein, Inc.
2026 Third Quarter and Year -to-Date
Reconciliation of reported GAAP net income to Adjusted EBITDA
(in millions)
(unaudited)
Third Quarter
Year-to-Date
2026
2025
2026
2025
Net income attributable to Henry Schein, Inc. (GAAP)
$
119
$
101
$
320
$
297
Net income attributable to noncontrolling interests
7
8
20
19
Net income (GAAP)
126
109
340
316
Definitional adjustments:
Interest income
(9)
(9)
(24)
(24)
Interest expense
42
38
124
111
Income taxes
37
28
109
94
Depreciation and amortization
86
80
250
229
Non-GAAP adjustments:
Restructuring and related costs
22
34
63
82
Cyber incident-insurance proceeds, net of third-party advisory expenses
-
-
-
(20)
Impairment of intangible assets
-
-
-
1
Change in contingent consideration
1
6
-
4
Costs associated with shareholder advisory matters and select implementation related value
creation consulting costs
18
10
37
24
Litigation settlements
1
2
1
3
Other adjustments:
Equity in earnings of affiliates, net of tax
(3)
(3)
(2)
(10)
Adjusted EBITDA (non-GAAP)
$
321
$
295
$
898
$
810
Adjusted EBITDA is a non-GAAP measure that we calculate in the manner reflected on Exhibit C. We define Adjusted EBITDA as net
income, excluding (i) net income attributable to noncontrolling interests, (ii) interest income and expense, (iii) income taxes, (iv)
depreciation and amortization, (v) restructuring and related costs, (vi) cyber incident-insurance proceeds, net of third-party advisory
expenses, (vii) impairment of intangible assets, (viii) change in contingent consideration, (ix) costs associated with shareholder advisory
matters and select implementation related value creation consulting costs, (x) litigation settlements, and (xi) equity in earnings of
affiliates, net of tax. Amounts may not sum due to rounding.
-15-
###
Exhibit D
Henry Schein, Inc.
2026 Third Quarter and Year -to-Date
Impact of Net Tariff Refunds and Remeasurement Gains on Earnings Per Share
(unaudited)
Third Quarter
Year -to-Date
2026
2025
Growth
2026
2025
Growth
GAAP diluted EPS attributable to Henry Schein, Inc.
$
1.06
$
0.84
26.2%
$
2.80
$
2.42
15.7%
Non-GAAP adjustments (1)
0.50
0.54
1.34
1.21
Non-GAAP diluted EPS attributable to Henry Schein, Inc.
1.56
1.38
13.0%
4.14
3.63
14.0%
Net tariff refunds benefit, net of tax (2)
(0.19)
-
(0.20)
-
Remeasurement gains, net of tax (3)
-
(0.23)
(0.07)
(0.26)
Adjusted non-GAAP diluted EPS attributable to Henry Schein, Inc.
$
1.37
$
1.15
19.1%
$
3.87
$
3.37
14.8%
Management presents adjusted non-GAAP diluted EPS excluding net tariff refund benefits and remeasurement gains as we believe this presentation facilitates
comparison of the Company's underlying operating performance between periods.
(1) See Exhibit B for adjustments reconciling GAAP diluted EPS attributable to Henry Schein, Inc. to non-GAAP diluted EPS attributable to Henry Schein,
Inc.
(2) Represents the net benefit, net of tax, from the International Emergency Economic Powers Act (IEEPA) tariff refunds recognized during the period.
(3) Represents the benefits, net of tax, related to remeasurement to the fair value of previously held equity investments.